OmniAb, Inc.
As of Oct 22, 2026, OmniAb is in Stage 2, the uptrend phase, now in week 21 (since Jun 1, 2026). It closed at $4.78, 5.2% below its 52-week high and above its 200-day average, which is rising.
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United S… More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care
Is OABI early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
OABI among Biotechnology22nd of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …22 | OABI | Stage 2 · wk 21 | 98 | −0.2% |
OmniAb: quick answers
What stage is OmniAb in?
As of Oct 22, 2026, OmniAb (OABI) is in Stage 2, the uptrend phase. It entered Stage 2 on Jun 1, 2026 and is in week 21. What the four stages mean
Is OmniAb in an uptrend?
Yes. OmniAb is in a Stage 2 uptrend. It trades 83.1% above its 200-day average, which is rising.
How far is OmniAb from its 52-week high?
OmniAb closed at $4.78 on Oct 22, 2026, 5.2% below its 52-week high of $5.04. Its 52-week low is $1.36.
How has OmniAb performed over the past year?
As of Oct 22, 2026, OmniAb is up 188.0% over the past year and up 154.3% so far in 2026.
Which sector and industry is OmniAb in?
OmniAb is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts. Its OmniAb platform's Biological Intelligence powers the immune systems of its proprietary and engineered transgenic animals to create optimized antibody candidates for human therapeutics. The company offers animal-based technologies include OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences; OmniFlic, a bispecific rat and OmniClic, a bispecific chicken are designed for discovery of bispecific antibody applications; OmniTaur, which provides cow-inspired antibodies with unique structural characteristics for challenging targets; OmnidAb, an in vivo platform for the discovery of single-domain antibodies based upon a human VH scaffold; and OmniDeep, a suite of in silico, an artificial intelligence (AI) and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. It has an agreement with mAbsolve Ltd. for its Fc-silencing platform technology to incorporate the STR technology into antibodies that have been generated using OmniAb's antibody discovery platform. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.